drugset / Trial / NCT00742248
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
54 enrolled
Chiesi Farmaceutici S.p.A.
Cardarelli Hospital · collabCarlo Mereu "Struttura complessa di Pneumologia", S. Corona Hospital, Pietra Ligure (Savona), Italy · collabFondazione Don Carlo Gnocchi ETS · collabGiovanni Barisione "Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria", S. Martino Hospital, Genoa, Italy · collabRoberto Dal Negro "Unità Operativa di Pneumologia", Hospital of Bussolengo (Verona), Italy · collabUniversita degli Studi di Genova · collabUniversity of Modena and Reggio Emilia · collabUniversity of Pisa · collabVito Brusasco "Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Italy (Co-ordinating centre) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to demonstrate equivalent efficacy between two different formulations of formoterol (pMDI using HFA-134 propellant and dry powder) on lung function in adult patients with partially reversible COPD.
Timeline
- Start
- 2004-09
- Primary completion
- 2005-05
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Formoterol | Other / unclassified | 12 ug | Inhaled |